Clinical Trial Update: Pazopanib in Molecularly Selected Patients With Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update of Pazopanib in molecularly selected patients with advanced non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-07-14